ArticleTanaffos2025
Iron Supplementation in Anemic Patients with Cystic Fibrosis: Effects on Hematologic, Clinical, and Pulmonary Outcomes.
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cystic fibrosis (CF) is an autosomal recessive multisystem disorder frequently complicated by anemia. This study aimed to evaluate the clinical, laboratory, radiological, and functional outcomes of oral iron therapy in anemic patients with CF. Materials and Methods: In this interventional before-after study, 340 patients with confirmed CF were screened for anemia. Twenty-two patients met the diagnostic criteria for anemia, and 15 completed the study and were included in the final analysis. Participants received oral ferrous sulfate at a dose of 4-6 mg/kg/day (maximum 150 mg/day) for 6-8 weeks. Demographic characteristics, CBC, iron profile, inflammatory markers, pulmonary function tests, sputum culture, high-resolution computed tomography (HRCT) findings, and Shwachman-Kulczycki scores were evaluated before and after treatment. Results: The prevalence of anemia among patients with CF was 6.47% (22/340). The mean age of participants was 18.8±1.24 years, and 53.3% were male. Hemoglobin and hematocrit levels increased significantly following treatment, with the greatest improvement observed among patients with combined iron deficiency anemia (IDA) and anemia of chronic inflammation (ACI) (p=0.007 and p=0.014, respectively). Serum iron levels also increased significantly after treatment (p=0.040). No significant changes were observed in pulmonary function indices, sputum culture results, or HRCT findings. Physical examination scores within the Shwachman-Kulczycki assessment improved significantly in the IDA+ACI group (p=0.039). Hemoglobin and ferritin levels showed significant direct and inverse correlations with the total Shwachman-Kulczycki score, respectively (p=0.003 and p=0.015). Conclusion: Short-term oral ferrous sulfate therapy improved hematologic and selected clinical outcomes in anemic CF patients without evidence of worsening pulmonary infection or respiratory status. Accurate identification of anemia etiology and appropriate management may improve patient outcomes, although longer-term follow-up studies are warranted.
Indexed as
Identifiers
42757307PMC13585149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.